Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers

Tags: ASCO GI Conference CoverageEsophagealLiver (includes HCC, Billiary Tract)

Published: 15 January 2021

Recent Videos

video

Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...

video

Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial

Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...

video

Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma

Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...

video

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...

video

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...

video

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial

video

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial

video

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

Related Videos

video-image

Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

video-image

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

video-image

Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial

video-image

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

video-image

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

video-image

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

video-image

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

video-image

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

video-image

Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer

video-image

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

video-image

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

video-image

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

video-image

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

video-image

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

video-image

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer